Landauer — Investor Presentation (December 2016)
25 slides from Landauer's investor presentation, Dec 15, 2016
Slide 1: Investor Presentation December 2016
LANDAUER’ Investor Presentation December 2016
Slide 2: Safe Harbor Statement
LANDAUER’ Safe Harbor Statement Some of the information shared here (including, in particular, the section titled “Fiscal Year 2017 Outlook’) constitutes forward-looking statements that are based on assumptions and involve certain risks and uncertainties. These include the following, without limitat
Slide 3: Compelling Investment Opportunity
LANDAUER’ Compelling Investment Opportunity + Industry-leading technology; proprietary Optically Stimulated Lu manufacturing process yescence (OSL) crystal Global Leader in Occupational Radiation Products and Services + Installed based of over 73,000 customers; 1.8 million individuals served * 90% r
Slide 4: Leading OSL Technology Supported by Proven Process
LANDAUER’ Leading OSL Technology Supported by Proven Process Current Monthly Process (~15 million badges annually) Technology Order placed; unique s Signed for e: = “Gold standard” in accuracy Dosimetry Reports = Proprietary OSL crystal technology with results are manufactured internally made availa
Slide 5: Serving Diverse End Markets Across Three Verticals
LANDAUER’ Serving Diverse End Markets Across Three Verticals wpe A Acute Care Professional -, $149 Million in FY 2016 Revenue Hospitals Offices Industrial Estimated U.S. Market Share - Dosimetry Acute Care 74% Hospitals fF Professiona| % Offices Regional Hospitals Veterinarian Emergency Response i n
Slide 6: Strong Global Footprint
LANDAUER’ Strong Global Footprint Well-positioned to serve an expanding global customer base of ~75,000 clients @ Service Labs
Slide 7: Significant International Growth Opportunity
LANDAUER’ Significant International Growth Opportunity Estimated 25% international market share provides ample room for continued growth FY GAAP 2016 Revenue Additional $1.5 million in Equity Income from International Joint Ventures int Venture Location Nagase-LANDAUER Japan Epsilon LANDAUER Turkey
Slide 8: U.S. Healthcare Trends are Fueling Opportunity
LANDAUER’ U.S. Healthcare Trends are Fueling Opportunity New Compliance Standards Tougher State Regulations + Heightened i Diagnostic Healthcare Emerging iaaging Consolidation + Pennsylvania Requirements ; oe from The Joint Evolving + Larger buying $| Gallfornia Commission Treatments groups create +
Slide 9: Uniquely Positioned to Capitalize on Demand for Solutions
LANDAUER’ Uniquely Positioned to Capitalize on Demand for Solutions Solutions Platform Reports: Analytics: Benchmarking: Training: Continuous Necessary for Context to Relevance to peers Assures Improvement: compliance information compliance and Integrated data patient across the enterprise outcomes
Slide 10: Strategic Path Forward
LANDAUER’ Strategic Path Forward Launch and commercialization of Verifii™ platform = Intermittent analog measurement > Connected digital platform Connect: to Real Time Data Provide customers with timely, actionable compliance solutions Generate meaningful cost benefits Shift the market focus . = Sim
Slide 11: Verifii: Redefining Our Core Technology
LANDAUER’ Verifii™: Redefining Our Core Technology A truly differentiated product and platform for incremental growth wérifii = Provides customers with a scalable, digital platform that connects employees to their environment = Eliminates fragmented manual processes enabling focus on building a robu
Slide 12: Creating a New Standard with Digital Dosimetry
LANDAUER’ Creating a New Standard with Digital Dosimetry ~30 million incidents measured annually (~1% physically handled) Real-time and historic data & Data is analytics processed are and stored in 7 the cloud available to client via web& mobile app: Allows customers to track trends, monitor event s
Slide 13: Significant Opportunities Across Core Verticals
LANDAUER’ Significant Opportunities Across Core Verticals Acute Care Hospitals Professional Office Penetrate Industrial Customize = Allows customers to outsource compliance and safety solution to NDAUER at a lower cost = 74% estimated U.S. market share = Consulting force in place to meet demand from
Slide 14: Balanced Approach to Capital Allocation
LANDAUER’ Fund Competitive Dividend Investin the Business Pay Down Debt Balanced Approach to Capital Allocation Currently 2%-3% dividend yield Long history of paying competitive dividend for over 20 years Core business investments focused on top and bottom line growth = Emphasis on higher margin, an
Slide 15: Compelling Investment Opportunity
LANDAUER’ Global Leader Occupational Radiation Products and Services Increased Regulation Drives Demand Compelling Growt! and Expansion Opportunities Strong Financial G Profile Compelling Investment Opportunity Industry-leading technology; proprietary Optically Stimulated Luminescence (OSL) crystal
Slide 16: Financial Overview
LANDAUER’ Financial Overview
Slide 17: LANDAUER Financial Overview
LANDAUER’ LANDAUER Financial Overview = Approximately 90% of revenue derived from subscriptions and is recurring in Revenue ($ in millions, FYE 9/30) nature $155.1 = 2016 Revenues of $149.2 million impacted $149.7 $151.3 aa dividend, reinvestmentin the core business and capital required to support s
Slide 18: Q4 FY16 Financial Highlights
LANDAUER’ Q4 FY16 Financial Highlights Key Q4 FY 2016 Financial Drivers + Revenue of $36.8 million in the fourth quarter of fiscal 2016 includes ($3.2 million) impact of our divested Radon and Medical Products businesses - No military product sales in the fourth quarter compared to $2 million in the
Slide 19: Q4 FY2016 and Q4 FY2015 Comparable Results
LANDAUER’ Q4 FY2016 and Q4 FY2015 Comparable Results Qa Fy2016 Q4 FY2016 Q4 FY2016 (§ Millions) parstinsn Medical Products Seaoal (ae Bo ties Adjustment Adjustment Divestitures* Revenue $36.8 $- $- $36.8 Operating Income $5.4 $- $- $5.4 Qa FY2015 Qa FY2015 Q4 FY2015 2 (§ Millions) ec ncs Medical Pro
Slide 20: Full Year FY2016 and FY2015 Comparable Results
LANDAUER’ Full Year FY2016 and FY2015 Comparable Results pouie Fy2016 Fy2016 Fy2016 ($ Millions) As Reported | Medical Products Radon Comparable, Excluding Adjustment Adjustment Divestitures * Revenue $149.2 $(5.8) $(0.1) $143.3 Operating Income $26.6 $(1.0) $(0.1) $25.5 Aes FY2015 FY2015 FY2015 ($
Slide 21: Q4 FY2016 and Q4 FY2015 Adjusted Results
LANDAUER’ Q4 FY2016 and Q4 FY2015 Adjusted Results 2 | Adjustment to ($ Millions) pens) Neneh sees Based es esenires ice! s Reporte ompensation xpenses ALE Revenue $36.8 - - - Net Income $2.6 $0.5 - $11 Adjusted EBITDA* $8.6 $0.8 - - Q4FY2015 _|Non-cash Stock Based! Reorganizationand |Loss on Divest
Slide 22: Fiscal Year 2017 Outlook
LANDAUER’ Fiscal Year 2017 Outlook Fiscal Year 2017 Outlook FY 2016 meee Excluding wig: | gudhen cen Divested Fiscal Year ($ Millions) . ae Businesses, Gain 2017 orind Other | onDivestiture Guidance pokes and Other sean Expenses* Revenue $149.2 ($5.9) $143.3 $149-$154 Diluted EPS $1.85 ($0.22) $1.63
Slide 23: Appendix
LANDAUER’ Appendix
Slide 24: Business Facts
LANDAUER’ Business Facts * Headquartered in Glenwood, IL * Founded in 1954 = Approximately 650 employees * 8 global markets = 73,000 annual customers served; 1.8M annual individuals served = 94%+ Customer retention rates LANDAUER at a Glance Proven Technology Platform = Industry standard OSL technol
Slide 25: Use of Non-GAAP Financial Measures
LANDAUER’ Use of Non-GAAP Financial Measures Management believes the disclosure of certain non-GAAP financial measures enhances investor understanding of our financial performance. Non-GAAP financial measures disclosed in this report include: Adjusted EBITDA, Adjusted Net Income, Pro Forma Revenue,